Journal of Clinical Trials
Open Access
ISSN: 2167-0870
ISSN: 2167-0870
Department of Medical Managed Markets and Health Economics and Outcomes Research, Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, South San Francisco, CA, USA
Dr. Janis A. Pruett is currently working in Department of Medical Managed Markets and Health Economics and Outcomes Research, Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, South San Francisco, CA, USA. He has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. He has extended his valuable service towards the scientific community with his extensive research work.
Research Article
Prognostic Value of Risk Assessment Tools for Patients with Pulmonary Arterial Hypertension in WHO Functional Class II: A Post Hoc Analysis of the EARLY Trial
Author(s): Nick H. Kim*, Cassandra A. Lickert, Janis A. Pruett, Carol Zhao and William Drake III
Background: Current practice guidelines for patients with Pulmonary Arterial Hypertension (PAH) recommend a multidimensional risk assessment, but World Health Organization (WHO) Functional Class (FC) remains a main criterion for treatment decisions.
Objectives: A post hoc analysis was conducted to determine if different risk assessment tools evaluated in PAH registry populations can identify patients in WHO FC II at higher risk of death.
Methods: Patients in the randomized, controlled EARLY trial (NCT00091715; N=185), which exclusively enrolled patients in FC II, were stratified into three categories—low-, intermediate-, and high-risk—using the original REVEAL risk calculator, revised REVEAL risk calculator 2.0, COMPERA categorical score, and two FPHN methods (invasive and non-invasive) counting low-ris.. View More»